Status:
COMPLETED
Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients
Lead Sponsor:
University of Rome Tor Vergata
Conditions:
Covid19
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
COVID-19 is considered an ongoing international global health problem which already caused 12 million confirmed cases. No specific effective treatment has been identified so far, and available support...
Detailed Description
COVID-19 is considered an ongoing international global health problem which already caused 12 million confirmed cases. No specific effective treatment has been identified so far, and available support...
Eligibility Criteria
Inclusion
- Eligible patients were over 20years old, with a confirmed positivity to COVID-19 at the oropharyngeal swab
Exclusion
- pregnant and lactating women, patients taking nitric oxide and nitrates, patients with reported allergy to milk proteins, patients with a previous history of bronchial hyperactivity and patients with pre-existing respiratory diseases. COVID-19 patients requiring intensive care or mechanical ventilation were excluded.
Key Trial Info
Start Date :
April 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2020
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT04475120
Start Date
April 15 2020
End Date
July 2 2020
Last Update
May 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rome Tor Vergata
Rome, Italy, 00133